Cara Therapeutics, Inc.
4 Stamford Plaza 107 Elm Street, 9th floor
Stamford
Connecticut
06902
United States
Tel: 203-567-1500
Fax: 203-567-1510
Website: http://www.caratherapeutics.com/
Email: info@caratherapeutics.com
About Cara Therapeutics, Inc.
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated activity in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.
CR845 is a peripherally acting kappa opioid receptor agonist currently in development for the treatment of acute and chronic pain and pruritus. In multiple randomized, double-blind, placebo-controlled Phase 2 trials in patients undergoing laparoscopic hysterectomy or bunionectomy procedures, I.V. CR845 treatment resulted in statistically significant reductions in both pain intensity and opioid-related side effects. In more than 440 subjects dosed to date, I.V. CR845 was observed to be well tolerated, without incurring the dysphoric and psychotomimetic side effects that have been reported with centrally acting (CNS-active) kappa opioid receptor agonists. Cara recently initiated its Phase 3 program with I.V. CR845 in postoperative pain. Cara also has an ongoing Phase 2 trial of an oral tablet formulation of CR845, for the treatment of osteoarthritis (OA).
224 articles with Cara Therapeutics, Inc.
-
Cara Therapeutics Releases Inaugural Environmental, Social, and Governance Report
3/14/2023
Cara Therapeutics, Inc. released its inaugural Environmental, Social, and Governance report highlighting the Company’s efforts in key areas such as corporate governance, diversity and inclusion in the workplace, environmental stewardship and social responsibility.
-
Cara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results
3/6/2023
Cara Therapeutics, Inc. today announced financial results and operational highlights for the fourth quarter and full year ended December 31, 2022.
-
Cara Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
2/21/2023
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, March 6, 2023, at 4:30 p.m. EST to report fourth quarter and full year 2022 financial results and provide a corporate update.
-
Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine
2/8/2023
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the New England Journal of Medicine (NEJM) has published results from the KOMFORT Phase 2 clinical trial of oral difelikefalin in patients with moderate-to-severe pruritus from notalgia paresthetica.
-
Cara Therapeutics Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference
1/3/2023
Cara Therapeutics, Inc. announced that Christopher Posner, President and Chief Executive Officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, at 11:15 a.m. PST in San Francisco, CA.
-
Cara Therapeutics Reports Third Quarter 2022 Financial Results
11/7/2022
Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, announced financial results and operational highlights for the third quarter ended September 30, 2022.
-
Cara Therapeutics Announces Appointment of Lisa von Moltke, M.D., to its Board of Directors
11/3/2022
Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, announced the appointment of Lisa von Moltke, M.D., to its Board of Directors.
-
Cara Therapeutics to Present at Upcoming Investor Conferences - November 02, 2022
11/2/2022
Cara Therapeutics, Inc. announced that members of its Executive Leadership Team will present at the following investor conferences.
-
Cara Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022
10/24/2022
Cara Therapeutics, Inc. today announced the Company will host a conference call and live audio webcast on Monday, November 7, 2022, at 4:30 p.m. ET to report third quarter 2022 financial results and provide a corporate update.
-
Biopharma and life science companies added changes to their leadership teams this week, with Cara Therapeutics, SOTIO Biotech, Agenus, and more filling several C-suite positions.
-
Cara Therapeutics Presents Late-Breaking Results of the KOMFORT Phase 2 Trial of Oral Difelikefalin for Pruritus in Notalgia Paresthetica at the 31st EADV Congress
9/8/2022
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced results from the KOMFORT Phase 2 clinical trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in notalgia paresthetica (NP).
-
Cara Therapeutics to Host Virtual Notalgia Paresthetica Event on September 20, 2022
8/24/2022
Cara Therapeutics, Inc. today announced the Company will host a virtual event focused on notalgia paresthetica (NP) on Tuesday, September 20, 2022, from 11:00 a.m. to 12:15 p.m. ET.
-
Cara Therapeutics Announces KOMFORT Data Accepted for Late-Breaking Presentation at the 31st EADV Congress
8/22/2022
Cara Therapeutics, Inc. today announced data from the KOMFORT Phase 2 clinical trial evaluating oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica will be presented during a late-breaking news session at the 31st European Academy.
-
Cara Therapeutics Reports Second Quarter 2022 Financial Results
8/8/2022
Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, announced financial results and operational highlights for the second quarter ended June 30, 2022.
-
Cara Therapeutics to Announce Second Quarter 2022 Financial Results on August 8, 2022
8/1/2022
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, August 8, 2022, at 4:30 p.m. ET to report second quarter 2022 financial results and provide a corporate update.
-
Cara Therapeutics to Present at Upcoming Investor Conferences
5/17/2022
Cara Therapeutics, Inc. today announced that Christopher Posner, President and Chief Executive Officer, will present at the following investor conferences: H.C. Wainwright Global Investment Conference Wednesday, May 25, 2022, at 10:30 a.m. ET.
-
Cara Therapeutics to Present at May 2022 Investor Conferences
5/3/2022
Cara Therapeutics, Inc. announced that Christopher Posner, President and Chief Executive Officer, will present at the following investor conferences in May.
-
Cara Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022
4/29/2022
Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, May 9, 2022, at 4:30 p.m. ET to report first quarter 2022 financial results and provide a corporate update.
-
Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients
4/28/2022
Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics, Inc. announced that the European Commission has granted marketing authorization to Kapruvia® for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients.
-
Clinical Catch-Up: COVID-19, AAN, ACC
4/11/2022
It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look.